{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:08:39Z","timestamp":1790446119201,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ebiom.2022.104217","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T08:38:48Z","timestamp":1660293528000},"page":"104217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1\/2 and phase-2 clinical trials"],"prefix":"10.1016","volume":"83","author":[{"given":"Subhash","family":"Thuluva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Paradkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subba Reddy","family":"Gunneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Yerroju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6638-7701","authenticated-orcid":false,"given":"Rammohan","family":"Mogulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kyasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil Kumar","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Medigeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-7873","authenticated-orcid":false,"given":"Janmejay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-070X","authenticated-orcid":false,"given":"Heena","family":"Shaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5568-7036","authenticated-orcid":false,"given":"Chandramani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateshwar","family":"Rao A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104217_bib0001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0002","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1016\/j.jaip.2021.07.016","article-title":"SARS-CoV-2 vaccines: where are we now?","volume":"9","author":"Flanagan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ebiom.2022.104217_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.104217_bib0004","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.104217_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129893","article-title":"Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate","volume":"1865","author":"Chen","year":"2021","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.ebiom.2022.104217_bib0006","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1080\/21645515.2021.1901545","article-title":"SARSCoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","volume":"17","author":"Pollet","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ebiom.2022.104217_bib0007","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1007\/s00253-021-11281-3","article-title":"Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain\u2013based vaccine candidate, RBD219-N1C1","volume":"105","author":"Lee","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.ebiom.2022.104217_bib0008","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1016\/j.vaccine.2020.09.061","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.104217_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.106003","article-title":"Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate","volume":"190","author":"Chen","year":"2022","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.ebiom.2022.104217_bib0010","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"Dispinseri","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104217_bib0011","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.4049\/jimmunol.2000717","article-title":"Expansion of SARS-CoV-2-Specific antibody-secreting cells and generation of neutralizing antibodies in hospitalized COVID-19 patients","volume":"205","author":"Varnait\u0117","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2022.104217_bib0012","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104217_bib0013","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104217_bib0014","unstructured":"LIAISON\u00ae SARS-CoV-2 S1\/S2 IgG. The fully automated serology test for the detection of SARS-CoV-2 IgG antibodies, Saluggia; Italy."},{"key":"10.1016\/j.ebiom.2022.104217_bib0015","unstructured":"Data Sheet NIBSC. Research Reagent for Anti-SARS-CoV-2 Ab NIBSC Code 20\/130. Medicines and Healthcare products Regulatory Agency, Hertfordshire, United Kingdom."},{"key":"10.1016\/j.ebiom.2022.104217_bib0016","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ebiom.2022.104217_bib0017","article-title":"Establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody","author":"Mattiuzzo","year":"2020","journal-title":"World Health Organization, Geneva"},{"key":"10.1016\/j.ebiom.2022.104217_bib0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-1759(95)00127-V","article-title":"Cytokine-based human whole blood assay for the detection of antigen-reactive T cells","volume":"186","author":"Petrovsky","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ebiom.2022.104217_bib0019","series-title":"Guidelines on Clinical Evaluation of Vaccines","first-page":"1","year":"2015"},{"key":"10.1016\/j.ebiom.2022.104217_bib0020","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, Phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104217_bib0021","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.671633","article-title":"Antibodies and vaccines target RBD of SARS-CoV-2","volume":"8","author":"Min","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ebiom.2022.104217_bib0023","article-title":"SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential","volume":"1","author":"Neidleman","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0024","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00277-020-04066-7","article-title":"Signals of Th2 immune response from COVID-19 patients requiring intensive care","volume":"99","author":"Roncati","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ebiom.2022.104217_bib0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104217_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ebiom.2022.104217_bib0027","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104217_bib0028","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0029","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine Dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104217_bib0031","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104217_bib0032","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:40Z","timestamp":1762456900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422003991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":32,"alternative-id":["S2352396422003991"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104217","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.08.22271822","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1\/2 and phase-2 clinical trials","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104217"}}